Concourse Financial Group Securities, Inc. Kintara Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

  • $1.64 Billion
  • Q3 2024

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 15, 2022
BUY
$0.14 - $6.8 $0 - $0
0 New
0 $0
Q2 2022

Aug 09, 2022
BUY
$0.14 - $0.5 $0 - $0
0 New
0 $0
Q1 2022

May 09, 2022
BUY
$0.31 - $0.55 $0 - $0
0 New
0 $0
Q4 2021

Feb 07, 2022
BUY
$0.51 - $1.04 $0 - $0
0 New
0 $0
Q3 2021

Nov 09, 2021
BUY
$0.82 - $2.3 $0 - $0
0 New
0 $0
Q2 2021

Aug 13, 2021
BUY
$1.26 - $2.4 $0 - $0
0 New
0 $0
Q1 2021

May 13, 2021
BUY
$1.32 - $2.74 $0 - $0
0 New
0 $0
Q4 2020

Feb 02, 2021
BUY
$1.26 - $1.72 $0 - $0
0 New
0 $0
Q3 2020

Nov 13, 2020
BUY
$0.63 - $1.7 $0 - $0
0 New
0 $0

About Kintara Therapeutics, Inc.

KTRA Quotes by TradingView
  • Ticker KTRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 80,807,296
  • Market Cap $17.8M
  • Description
  • Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...
More about KTRA
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email